There are a lot of things going on at the troubled Food and Drug Administration right now that could have a profound impact on the future of diabetes care, but most of us patients never hear about them. And that’s a damn shame. Because we stand at a crossroads.
You may or may not be aware that the Obama Administration is about to appoint a new FDA Commissioner. The politics and personal leanings of this…
I met Alexis at the recent BDI luncheon for women with Type 1 diabetes. She seemed bubbly and smart, and I felt an instant connection. When I discovered her job title was “Compliance Analyst,” I just had to hear more about that. Turns out it’s not quite what you think, but fascinating nevertheless.
A Guest Post by Alexis Pollack —
Compliance Analyst, Amylin Pharmaceuticals, Inc.
Type 1 diabetes for 15 years
Compliance. It’s not a…
I noticed a lot of chatter of late on diabetes forum sites about Symlin use. Some are still on the fence about trying this synthetic form of the human hormone Amylin, normally made by the beta cells, which helps level out post-meal glucose peaks. Others are just grateful that it’s now available in a convenient injection pen.
In early June, Amylin reported results of a study using Symlin with 112 patients with Type 2 diabetes,…